X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will support the continuation of the ongoing research collaboration between Aegis Life and Entos Pharmaceuticals, developing novel DNA-based encoded antibody therapeutics against HIV and malaria using the Entos Fusogenix PLV nucleic acid delivery technology.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: $4.4 million Upfront Cash: Undisclosed
Deal Type: Financing March 19, 2024
Details:
The funding will be used to develop the Fusogenix PLV platform for the delivery of DNA-encoded monoclonal antibodies, including HIVV-102, directly inside the patient’s cells for the treatment of infectious diseases such as HIV, influenzas, and malaria.
Lead Product(s): DNA-encoded Monoclonal Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding June 07, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
